Paper25901682
Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Kreiter S and 14 others. Nature, 2015. Cited by 1,051 papers, by iCite.
Cite this record
ConductScience Library. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Papers, record 25901682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25901682
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Epitopes, T-Lymphocyte | Major topic |
| Histocompatibility Antigens Class II | Major topic |
| Immunotherapy | Major topic |
| Melanoma, Experimental | Major topic |
| Mutation | Major topic |
| Algorithms | |
| Animals | |
| CD4-Positive T-Lymphocytes | |
| Cancer Vaccines | |
| Computer Simulation | |
| Disease Models, Animal | |
| Exome | |
| Female | |
| Humans | |
| Mice | |
| Precision Medicine | |
| Sequence Analysis, DNA | |
| Survival Analysis |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 AI107010 | NIAID NIH HHS | United States | R01AI107010 | PubMed and NIH |
Source NIH RePORTER
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Erratum in | 26040715 | Erratum: Mutant MHC class II epitopes drive therapeutic immune responses to cancer. | https://conductscience.org/library/papers/26040715 | PubMed |
| Comment in | 26032267 | Cancer immunotherapy: exploiting neoepitopes. | https://conductscience.org/library/papers/26032267 | PubMed |
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18026089 | Adaptive immunity maintains occult cancer in an equilibrium state. | Nature | 2007 | https://conductscience.org/library/papers/18026089 | PubMed |
| 2 | 25428504 | Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. | Nature | 2014 | https://conductscience.org/library/papers/25428504 | PubMed |
| 3 | 10334988 | Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. | Science | 1999 | https://conductscience.org/library/papers/10334988 | PubMed |
| 4 | 16940422 | Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. | Blood | 2006 | https://conductscience.org/library/papers/16940422 | PubMed |
| 5 | 9058806 | Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. | J Immunol | 1997 | https://conductscience.org/library/papers/9058806 | PubMed |
| 6 | 7652577 | A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. | Science | 1995 | https://conductscience.org/library/papers/7652577 | PubMed |
| 7 | 25428505 | PD-1 blockade induces responses by inhibiting adaptive immune resistance. | Nature | 2014 | https://conductscience.org/library/papers/25428505 | PubMed |
| 8 | 25765070 | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. | Science | 2015 | https://conductscience.org/library/papers/25765070 | PubMed |
| 9 | 24812403 | Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. | Science | 2014 | https://conductscience.org/library/papers/24812403 | PubMed |
| 10 | 20410931 | Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. | Gene Ther | 2010 | https://conductscience.org/library/papers/20410931 | PubMed |
| 11 | 25043048 | A vaccine targeting mutant IDH1 induces antitumour immunity. | Nature | 2014 | https://conductscience.org/library/papers/25043048 | PubMed |
| 12 | 23690473 | Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. | J Immunol | 2013 | https://conductscience.org/library/papers/23690473 | PubMed |
| 13 | 21045153 | Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. | Cancer Res | 2010 | https://conductscience.org/library/papers/21045153 | PubMed |
| 14 | 22397650 | Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22397650 | PubMed |
| 15 | 18097032 | Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. | J Immunol | 2008 | https://conductscience.org/library/papers/18097032 | PubMed |
| 16 | 23028300 | Confidence-based somatic mutation evaluation and prioritization. | PLoS Comput Biol | 2012 | https://conductscience.org/library/papers/23028300 | PubMed |
| 17 | 24621249 | Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. | BMC Genomics | 2014 | https://conductscience.org/library/papers/24621249 | PubMed |
| 18 | 25531942 | High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. | Nat Med | 2015 | https://conductscience.org/library/papers/25531942 | PubMed |
| 19 | 23644516 | Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. | Nat Med | 2013 | https://conductscience.org/library/papers/23644516 | PubMed |
| 20 | 24104749 | The regulatory landscape for actively personalized cancer immunotherapies. | Nat Biotechnol | 2013 | https://conductscience.org/library/papers/24104749 | PubMed |
Cited by781
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,051 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42871894 | A bottleneck-first evaluation of antigen delivery platforms for therapeutic cancer vaccines. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/42871894 | PubMed |
| 42809703 | Improving peptide vaccine manufacturability without sacrificing immunogenicity: substitution of methionine and cysteine with oxidation-resistant isosteres. | J Immunol | 2026 | https://conductscience.org/library/papers/42809703 | PubMed |
| 42773266 | Metastasis enables immunogenicity through migrasome-mediated antigen release. | Nat Immunol | 2026 | https://conductscience.org/library/papers/42773266 | PubMed |
| 42722679 | Developing neoantigen cancer vaccines: where are we now? | Nat Commun | 2026 | https://conductscience.org/library/papers/42722679 | PubMed |
| 42696566 | Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity. | Sci Adv | 2026 | https://conductscience.org/library/papers/42696566 | PubMed |
| 42694098 | Cancer Immunotherapy: Therapeutic Limitations and Next-Generation Precision Strategies. | Immune Netw | 2026 | https://conductscience.org/library/papers/42694098 | PubMed |
| 42621703 | Overcoming Drug Resistance by Paclitaxel Resistance in Triple-Negative Breast Cancer. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42621703 | PubMed |
| 42595869 | Take Five: harmonization in personalized cancer vaccines for cancer immunotherapy. | Exp Mol Med | 2026 | https://conductscience.org/library/papers/42595869 | PubMed |
| 42588678 | The Central Role of HLA Class II-Restricted Helper Neoantigen Vaccines in Cancer Immunotherapy. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588678 | PubMed |
| 42541646 | Past achievements and future perspectives of personalized vaccines and the role of dendritic cells. | Immunol Res | 2026 | https://conductscience.org/library/papers/42541646 | PubMed |
| 42509551 | Benchmarking sequence-based and AlphaFold-based methods for pMHC-II binding core prediction: distinct strengths and consensus approaches. | BMC Med Genomics | 2026 | https://conductscience.org/library/papers/42509551 | PubMed |
| 42509244 | The Dendritic Cell-based Vaccine PROTEXI leverages Antiviral CD4 T cell Memory to boost anti-tumor immune responses in mice. | Nat Commun | 2026 | https://conductscience.org/library/papers/42509244 | PubMed |
| 42506600 | Minicircle DNA Vaccines: Overcoming Delivery and Expression Barriers in Next-Generation Immunization. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42506600 | PubMed |
| 42481451 | Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42481451 | PubMed |
| 42414668 | Chemically synthesized, non-capped and non-polyadenylated peptide-coding RNA efficiently induces antigen-specific CD8+ T cells. | Nat Biomed Eng | 2026 | https://conductscience.org/library/papers/42414668 | PubMed |
| 42344905 | Site-specific neoepitope induction by RNA editing reprograms tumor immunogenicity. | Front Immunol | 2026 | https://conductscience.org/library/papers/42344905 | PubMed |
| 42313973 | CD4+ T cells impair tumor growth through IL-3 and TNF-dependent vascular damage. | Science | 2026 | https://conductscience.org/library/papers/42313973 | PubMed |
| 42289978 | PMGen: from peptide-MHC structure prediction to peptide generation. | Bioinformatics | 2026 | https://conductscience.org/library/papers/42289978 | PubMed |
| 42256206 | CpG 1018 augments mRNA vaccine-induced anti-tumor immunity by potentiating CD8+ T cell responses. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42256206 | PubMed |
| 42244090 | Human Organoids as a Novel Tool for Vaccine Study. | Adv Healthc Mater | 2026 | https://conductscience.org/library/papers/42244090 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRCA1 | 672 | PubTator's text mining | https://conductscience.org/library/genes/672 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| EMB | 133418 | PubTator's text mining | https://conductscience.org/library/genes/133418 | NCBI Gene |
| HLA-DQA1 | 3117 | PubTator's text mining | https://conductscience.org/library/genes/3117 | NCBI Gene |
| HLA-DQB1 | 3119 | PubTator's text mining | https://conductscience.org/library/genes/3119 | NCBI Gene |
| HLA-DRB1 | 3123 | PubTator's text mining | https://conductscience.org/library/genes/3123 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25901682
GET https://conductscience.org/api/papers/v1/25901682/references?page=2